investiment.io
Kazia Therapeutics Limited
$0.5
-0.02 (-4.65%)
Kazia Therapeutics Limited
$0.5
-0.02 (-4.65%)
KZIA Price Chart
| Basic | |
|---|---|
| Market Cap | $9.94M |
| Price | $0.5 |
| 52 Week Range | 0.19-1.58 |
| Beta | 2.10 |
| Margins | |
| Gross Profit Margin | 100.00% |
| Operating Profit Margin | -3463115.00% |
| Net Profit Margin | -2804047.50% |
| Valuation (TTM) | |
| P/E Ratio | -1.14 |
| Price to Sales Ratio | 39807.07 |
| Price to Book Ratio | 3.41 |
| PEG Ratio | -0.01 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
9
IPO Date
1999-01-06T00:00:00.000Z
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Phone
1300 787 272
Address
Three International Towers, Sydney, NSW, 2000, AU
CIK
0001075880